Corrigendum
for de Martimprey et al., Nucl. Acids Res. 36 (1) e2.
Nucleic Acids Research 2008 36(21):6944; doi:10.1093/nar/gkn882
Nucleic Acids Research, 2008, Vol. 36, No. 21 6944
© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
Henri de Martimprey,
Jean-Remi Bertrand,
Alfredo Fusco,
Massimo Santoro,
Patrick Couvreur,
Christine Vauthier and
Claude Malvy
Nucleic Acids Res. (2008) 36, e2
The authors for this paper wish to apologize for an error in figure 1 of their paper. The correct version appears below.

View larger version (26K):
[in this window]
[in a new window]
[Download PowerPoint slide]
|
Figure 1. A: Design of ret/PTC1 small interfering RNAs (siRNAs). Location of ret/PTC1 sense sequence of siRNA nos. 1, 2, 3, 4 and 5 examined in this study are shown under the junction sequence of ret/PTC1. The ret part of the oncogene is presented on the right part ( ). B: The control sequence is the sequence #5 with four mismatches. Mismatch site is shown in boxes. C: Structure of the shRNA1 and negative control shRNA.
|
|

CiteULike
Connotea
Del.icio.us What's this?